Table 2 Number of immunomodulating therapy sessions. Data are presented as mean (range).

From: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients

Therapy

CRC (N = 21)

Pancreatic (N = 14)

CCC (N = 5)

Gastric (N = 5)

Esophageal (N = 4)

Locoregional mEHT

16.57 (6–42)

19.71 (2–47)

20.20 (13–35)

25.40 (13–51)

16.25 (5–44)

wIRA hyperthermia

2.10 (0–19)

1.93 (0–16)

2.60 (0–13)

5.80 (0–17)

0.25 (0–1)

Mild WBH

3.52 (0–8)

4.43 (1–8)

4.80 (3–7)

5.60 (0–15)

5.25 (2–10)

Moderate WBH

1.71 (0–15)

1.79 (0–13)

2.60 (0–9)

0.00 (0–0)

0.25 (0–1)

Long duration moderate WBH

1.00 (0–3)

2.14 (1–12)

1.20 (1–2)

2.60 (1–4)

1.00 (0–2)

Low-dose ipilimumab 1

3.57 (0–12)

3.36 (1–6)

4.20 (3–6)

5.00 (3–12)

6.00 (3–9)

Low-dose nivolumab 1

4.09 (1–12)

3.43 (1–7)

3.60 (2–6)

6.60 (3–12)

6.00 (3–9)

Interleukin-2

3.86 (1–22)

3.93 (1–14)

7.40 (1–18)

2.80 (1–5)

3.25 (1–6)

High-dose vitamin C

14.81 (2–35)

16.86 (4–38)

19.40 (13–36)

22.20 (13–34)

15.00 (5–37)

Curcumin

2.00 (0–21)

1.14 (0–12)

4.20 (0–15)

1.00 (0–5)

2.50 (0–10)

Dichloroacetate

1.71 (0–8)

3.14 (0–22)

5.40 (0–12)

1.60 (0–4)

4.00 (0–13)

Artesunate

2.05 (0–8)

0.86 (0–8)

5.20 (0–11)

1.00 (0–5)

0.00 (0–5)

Ozone therapy

0.81 (0–4)

1.07 (0–7)

2.40 (0–5)

0.00 (0–0)

0.50 (0–2)

Interferon-γ

1.57 (0–13)

2.64 (0–13)

3.80 (0–9)

1.00 (0–5)

0.00 (0–0)

Metronomic chemotherapy

0.57 (0–11)

3.93 (0–15)

1.20 (0–3)

5.40 (0–18)

2.75 (1–5)

  1. 1A single patient in the CRC cohort received nivolumab as monotherapy. CCC: cholangiocellular cancer; CRC: colorectal cancer; mEHT: modulated electro-hyperthermia; WBH: whole-body hyperthermia; wIRA: water-filtered infrared-A.
Back to article page